دورية أكاديمية
أعرض في EDS

Nano-Polyplexes Mediated Transfection of Runx2-shRNA Mitigates the Osteodifferentiation of Human Valvular Interstitial Cells.

التفاصيل البيبلوغرافية
العنوان: Nano-Polyplexes Mediated Transfection of Runx2-shRNA Mitigates the Osteodifferentiation of Human Valvular Interstitial Cells.
المؤلفون: Voicu G; Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, Bucharest, Romania., Rebleanu D; Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, Bucharest, Romania., Constantinescu CA; Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, Bucharest, Romania., Fuior EV; Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, Bucharest, Romania., Ciortan L; Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, Bucharest, Romania., Droc I; Central Military Hospital 'Dr. Carol Davila', Cardiovascular Surgery Clinic, Bucharest, Romania., Uritu CM; Centre of Advanced Research in Bionanoconjugates and Biopolymers, 'Petru Poni' Institute of Macromolecular Chemistry, 700487 Iasi, Romania.; Advanced Centre for Research-Development in Experimental Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania., Pinteala M; Centre of Advanced Research in Bionanoconjugates and Biopolymers, 'Petru Poni' Institute of Macromolecular Chemistry, 700487 Iasi, Romania., Manduteanu I; Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, Bucharest, Romania., Simionescu M; Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, Bucharest, Romania., Calin M; Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of the Romanian Academy, Bucharest, Romania.
المصدر: Pharmaceutics [Pharmaceutics] 2020 Jun 02; Vol. 12 (6). Date of Electronic Publication: 2020 Jun 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Calcific aortic valve disease (CAVD) is a progressive disorder that increases in prevalence with age. An important role in aortic valve calcification is played by valvular interstitial cells (VIC), that with age or in pathological conditions acquire an osteoblast-like phenotype that advances the disease. Therefore, pharmacological interventions aiming to stop or reverse the osteoblastic transition of VIC may represent a therapeutic option for CAVD. In this study, we aimed at developing a nanotherapeutic strategy able to prevent the phenotypic switch of human aortic VIC into osteoblast-like cells. We hypothesize that nanocarriers designed for silencing the Runt-related transcription factor 2 (Runx2) will stop the progress or reverse the osteodifferentiation of human VIC, induced by high glucose concentrations and pro-osteogenic factors. We report here the potential of fullerene (C60)-polyethyleneimine (PEI)/short hairpin (sh)RNA-Runx2 nano-polyplexes to efficiently down-regulate Runx2 mRNA and protein expression leading subsequently to a significant reduction in the expression of osteogenic proteins (i.e. ALP, BSP, OSP and BMP4) in osteoblast-committed VIC. The data suggest that the silencing of Runx2 could represent a novel strategy to impede the osteoblastic phenotypic shift of VIC and the ensuing progress of CAVD.
References: J Am Coll Cardiol. 2015 Aug 4;66(5):561-77. (PMID: 26227196)
Dev Dyn. 2000 Dec;219(4):461-71. (PMID: 11084646)
Integr Biol (Camb). 2012 Dec;4(12):1498-507. (PMID: 23146945)
J Am Heart Assoc. 2017 Sep 14;6(9):. (PMID: 28912209)
Am J Cardiol. 2020 Feb 15;125(4):589-596. (PMID: 31831151)
J Cell Mol Med. 2020 Jun;24(11):6350-6361. (PMID: 32307869)
Cardiology. 2015;130(1):55-61. (PMID: 25531888)
Circulation. 2006 Jul 4;114(1 Suppl):I547-52. (PMID: 16820635)
Cytotherapy. 2007;9(7):682-96. (PMID: 17917883)
Circ Res. 2011 May 27;108(11):1381-91. (PMID: 21617135)
Circulation. 2003 May 6;107(17):2181-4. (PMID: 12719282)
J Mol Cell Cardiol. 2016 May;94:13-20. (PMID: 26996755)
Nat Rev Dis Primers. 2016 Mar 03;2:16006. (PMID: 27188578)
Pharmaceutics. 2019 Jan 21;11(1):. (PMID: 30669699)
World J Cardiol. 2017 Aug 26;9(8):667-672. (PMID: 28932355)
Diab Vasc Dis Res. 2019 Nov;16(6):562-576. (PMID: 31530180)
Regen Med. 2018 Jan;13(1):41-54. (PMID: 29360011)
Biotechnol J. 2011 Sep;6(9):1130-46. (PMID: 21744502)
Circ Res. 2013 Jul 5;113(2):198-208. (PMID: 23833294)
Circ Res. 1986 Sep;59(3):310-20. (PMID: 3769149)
Aging Cell. 2016 Oct;15(5):853-60. (PMID: 27242197)
Diab Vasc Dis Res. 2019 Jul;16(4):310-323. (PMID: 30623669)
J Mater Chem B. 2015 Mar 28;3(12):2433-2446. (PMID: 32262120)
J Thorac Cardiovasc Surg. 2009 Oct;138(4):1008-15. (PMID: 19664780)
Diab Vasc Dis Res. 2019 May;16(3):254-269. (PMID: 30563371)
PLoS One. 2014 May 01;9(5):e96577. (PMID: 24788418)
Eur Cell Mater. 2014 Oct 23;28:269-86. (PMID: 25340806)
Atherosclerosis. 2018 Oct;277:60-65. (PMID: 30173080)
Biomaterials. 2015 Aug;60:42-52. (PMID: 25982552)
Nat Protoc. 2008;3(6):1101-8. (PMID: 18546601)
Atherosclerosis. 1987 Oct;67(2-3):199-214. (PMID: 3675714)
Inflammation. 2012 Jun;35(3):834-40. (PMID: 21935671)
J Mol Cell Cardiol. 2011 Mar;50(3):561-9. (PMID: 21163264)
Methods Mol Biol. 2010;629:141-58. (PMID: 20387148)
Int J Cardiol. 2013 Oct 3;168(3):2264-71. (PMID: 23452891)
J Mol Cell Cardiol. 2009 Dec;47(6):828-34. (PMID: 19695258)
J Mol Cell Cardiol. 2012 Mar;52(3):689-700. (PMID: 22248532)
Circulation. 2007 Sep 11;116(11 Suppl):I282-7. (PMID: 17846318)
Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2387-93. (PMID: 25189570)
Front Physiol. 2018 Nov 20;9:1635. (PMID: 30524301)
Cardiovasc Diabetol. 2013 Nov 05;12:161. (PMID: 24188692)
Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2283-91. (PMID: 25231636)
Chem Biol. 2012 Jan 27;19(1):60-71. (PMID: 22284355)
Eur J Echocardiogr. 2009 Aug;10(6):723-5. (PMID: 19406839)
JAMA. 1997 Mar 19;277(11):925-6. (PMID: 9062334)
J Am Coll Cardiol. 2009 Feb 10;53(6):491-500. (PMID: 19195606)
Connect Tissue Res. 2003;44 Suppl 1:109-16. (PMID: 12952183)
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1700-1708.e1. (PMID: 24703637)
معلومات مُعتمدة: Financing Contract no.115/13.09.2016/ MySMIS:104362 Competitiveness Operational Programme 2014-2020, Priority Axis1/Action 1.1.4; INTERA project contract no. 13PCCDI/2018 within PNCDI III Executive Unit for Financing Higher Education, Research, Development and Innovation (UEFISCDI)
فهرسة مساهمة: Keywords: Runx2; calcific aortic valve disease; nanocarriers; osteodifferentiation.; shRNA; valvular interstitial cells
تواريخ الأحداث: Date Created: 20200606 Latest Revision: 20200928
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7355966
DOI: 10.3390/pharmaceutics12060507
PMID: 32498305
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics12060507